Overview

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Status:
RECRUITING

Trial end date:
2029-06-30

Target enrollment:

Participant gender:

Summary

A Single-Arm, Prospective Clinical Study of Venetoclax Combined with Azacitidine Followed by Bridging Transplantation in Patients with High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)

Phase:

PHASE2

Details

Lead Sponsor:

Yehui Tan

Treatments:

Azacitidine
venetoclax